Pattern of use and clinical outcomes with rIX‐FP in pediatric/adolescent patients with haemophilia B in Italy: Results from IDEAL real‐world study

Ähnliche Einträge

• Real‐world experience of rIX‐FP prophylaxis at dosing intervals of 14 days or more in adult patients with haemophilia B in Italy – Results from IDEAL Part B
  von: Antonio Coppola, et al.
  Veröffentlicht: (2024)
• ORPHEE: A Real‐World Study on rIX‐FP Prophylaxis Use in Adolescent/Adult Patients With Hemophilia B
  von: Fabienne Volot, et al.
  Veröffentlicht: (2024)
• Real‐World Effectiveness and Safety of Damoctocog Alfa Pegol in Severe and Nonsevere Patients With Hemophilia A From the Prospective, Multinational, Ongoing HEM ‐ POWR Study
  von: Mark T. Reding, et al.
  Veröffentlicht: (2025)
• A post hoc analysis of PROTECT VIII kids assessing long‐term efficacy and safety of damoctocog alfa pegol in adolescents with severe haemophilia A
  von: Sanjay Ahuja, et al.
  Veröffentlicht: (2024)
• A post hoc analysis of PROTECT VIII Kids assessing long‐term efficacy and safety of damoctocog alfa pegol in adolescents with severe haemophilia A
  Veröffentlicht: (2024)